Citations

Institution: Mayo Clinic Clear

Showing 10 of 108152 citations.

Abstract 1135: Loss of HSulf-1 promotes defective autophagy and increased lipid droplet biogenesis in ovarian cancer
Roy, Debarshi , Khurana, Ashwani, Hammond, Edward , Dredge, Keith , Shridhar, Viji , Mondal, Susmita , He, Xiaoping

Cancer Research | August 5, 2015 | Volume: 75 | Issue: 15_Supplement | Pages: 1135-1135

10.1158/1538-7445.am2015-1135 Get It

Abstract Dysregulation of autophagy and altered metabolic pathways are frequently observed in cancer. Due to these alterations, pharmacological targeting of these two pathways simultaneously could provide a viable therapeutic option. Although the association between these two pathways is well characterized in metabolic disorders, it is not well defined in ovarian cancer (OVCA). In this regard, we found that loss of endosulfatase HSulf-1, a known putative tumor suppressor, suppresses LC3-GFP foci formation and promotes increased lipid droplet (LD) biogenesis suggesting that absence of HSulf-1 in OVCA affects both autophagy and lipid metabolism. While isogenic cells with genetic ablation of HSulf-1 (OV202Sh1/2 and TOV2223Sh1 cells) displayed LDs, the nontargeted control transduced (NTC) OV202 and TOV2223 cells had significantly less LDs. In contrast, Transmission Electron Micrographs (TEMs) showed that OV202 and TOV2223 NTC cells had significantly more autophagic vacuoles (AVs) compared to their isogenic ShRNA targeted cells. Conversely, ectopic expression of HSulf-1 in SKOV3 cells decreased the number of LDs and increased the number of AVs compared to vector transfected controls. Here we report that OV202Sh1 cells and HSulf-1 deficient OV2008 cells have increased p-cPLA2α(ser505) levels that are associated with biogenesis of large number of LDs with reduced AVs. Interestingly, pharmacological inhibition of cPLA2α with AACOCF3 in OV202Sh1 cells resulted in reduced LD biogenesis, inhibited colony formation and reduced tumorigenesis in vivo. More importantly, treatment of HSulf-1 deficient cells with HS mimetic PG545 which can compensate for loss of HSulf-1, reduced LD biogenesis, promoted autophagy and inhibited tumor growth in vivo. Collectively, these results show a critical role of HSulf-1 in regulating both autophagy and LD biogenesis in ovarian cancer. Citation Format: Debarshi Roy, Susmita Mondal, Ashwani Khurana, Xiaoping He, Edward Hammond, Keith Dredge, Viji Shridhar. Loss of HSulf-1 promotes defective autophagy and increased lipid droplet biogenesis in ovarian cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1135. doi:10.1158/1538-7445.AM2015-1135
Mobile Device-Based Applications for Childhood Anxiety Disorders
Whiteside, Stephen P. H.

Journal of Child and Adolescent Psychopharmacology | August 5, 2015 | Volume: 26 | Issue: 3 | Pages: 246-251

10.1089/cap.2015.0010 | PMID 26244903 Get It

Surgery of the Trachea
Allen, Mark S.

The Korean Journal of Thoracic and Cardiovascular Surgery | August 5, 2015 | Volume: 48 | Issue: 4 | Pages: 231-237

10.5090/kjtcs.2015.48.4.231 | PMID 26290833 Get It

Accuracy of the ABC/2 Score for Intracerebral Hemorrhage
Webb, Alastair J.S. , Ullman, Natalie , Morgan, Tim C., Muschelli, John , Kornbluth, Joshua , Awad, Issam A. , Rosenblum, Michael , Ziai, Wendy , Zuccarrello, Mario, Aldrich, François, John, Sayona , Harnof, Sagi , Lopez, George Α. , Broaddus, William C. , Wijman, Christine A.C., Vespa, Paul , Bullock, Ross, Haines, Stephen J. , Cruz‐Flores, Salvador , Tuhrim, Stan, Hill, Michael D. , Narayan, Raj K. , Hanley, Daniel F. , Tayal, Ashis , Díaz, Alberto Torres, Hoffer, Alan , Moheet, Asma , Agarwal, Sachin , Markowski, Mason, Rosenthal, Guy , Kureshi, Inam, Varelas, Panayiotis N. , Pinto, Pedro Telles Cougo, Camarata, Paul J. , Helms, Ann , Shahi, Kavian, Sinclair, David, Gizzi, Martin , LeDoux, David, Torbey, Michel , Cockroft, Kevin M. , Antezana, David, Margalit, Nevo, Crabtree, H. Mark, Lovick, Darren, Weaver, Michael, Leonardo, Jody, Ardelt, Agnieszka, Csiba, László , Wartenberg, Katja E. , Bösel, Julian , Adams, Harold P. , Hobohm, Carsten , Kerz, Thomas , Wechsler, Lawrence R. , Gardner, Paul A. , Decker, David A., Gonzales, Nicole R. , Caron, Jean-Louis, Hall, Christiana E., Ansari, Safdar , Luft, Andreas R. , Graham, R. Scott, Tucker, Kristi, Webb, Alastair Js , Mayo, Stephen L. , Martí‐Fábregas, Joan , Seder, David B. , Freeman, William D. , Lazaridis, Christos , LeDoux, David, Latorre, Julius Gene , Venkatasubramanian, Chitra , Jallo, Jack , Reinert, Michael , Butcher, Kenneth , Adeoye, Opeolu M , Testai, Fernando D. , Bulters, Diederik , Caron, Jean-Louis R., Arikán, Fuat , Hill, Michael D , Hanley, Daniel F , Lopez, George

Stroke | August 5, 2015 | Volume: 46 | Issue: 9 | Pages: 2470-2476

10.1161/strokeaha.114.007343 | PMID 26243227 Get It

Background and Purpose— The ABC/2 score estimates intracerebral hemorrhage (ICH) volume, yet validations have been limited by small samples and inappropriate outcome measures. We determined accuracy of the ABC/2 score calculated at a specialized reading center (RC-ABC) or local site (site-ABC) versus the reference-standard computed tomography–based planimetry (CTP). Methods— In Minimally Invasive Surgery Plus Recombinant Tissue-Type Plasminogen Activator for Intracerebral Hemorrhage Evacuation-II (MISTIE-II), Clot Lysis Evaluation of Accelerated Resolution of Intraventricular Hemorrhage (CLEAR-IVH) and CLEAR-III trials. ICH volume was prospectively calculated by CTP, RC-ABC, and site-ABC. Agreement between CTP and ABC/2 was defined as an absolute difference up to 5 mL and relative difference within 20%. Determinants of ABC/2 accuracy were assessed by logistic regression. Results— In 4369 scans from 507 patients, CTP was more strongly correlated with RC-ABC ( r 2 =0.93) than with site-ABC ( r 2 =0.87). Although RC-ABC overestimated CTP-based volume on average (RC-ABC, 15.2 cm 3 ; CTP, 12.7 cm3), agreement was reasonable when categorized into mild, moderate, and severe ICH (κ=0.75; P <0.001). This was consistent with overestimation of ICH volume in 6 of 8 previous studies. Agreement with CTP was greater for RC-ABC (84% within 5 mL; 48% of scans within 20%) than for site-ABC (81% within 5 mL; 41% within 20%). RC-ABC had moderate accuracy for detecting ≥5 mL change in CTP volume between consecutive scans (sensitivity, 0.76; specificity, 0.86) and was more accurate with smaller ICH, thalamic hemorrhage, and homogeneous clots. Conclusions— ABC/2 scores at local or central sites are sufficiently accurate to categorize ICH volume and assess eligibility for the CLEAR-III and MISTIE III studies and moderately accurate for change in ICH volume. However, accuracy decreases with large, irregular, or lobar clots. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: MISTIE-II NCT00224770; CLEAR-III NCT00784134.
Abstract SY08-03: Targeting chromatin regulation for cancer therapy: progress towards chemical probes for methyl-lysine readers
James, Lindsey I. , Stuckey, Jake I., Baughman, Brandi M. , Perfetti, Michael T., Dickson, Brad M., Norris, Jacqueline L., Dong, Aiping , Kireev, Dmitri , Janzen, William P., McBride, Kevin M. , Mer, Georges , Frye, Stephen V. , Pattenden, Samantha G. , Cui, Gaofeng , Mäder, P. , Mu, Yunxiang , Rothbart, Scott B. , Strahl, Brian D. , Min, Jinrong , Brown, Peter J. , Bedford, Mark T. , Arrowsmith, C.H.

Cancer Research | August 5, 2015 | Volume: 75 | Issue: 15_Supplement | Pages: SY08-03-SY08-03

10.1158/1538-7445.am2015-sy08-03 Get It

Abstract Methyl-lysine (Kme) recognition domains play a central role in epigenetic regulation during cellular differentiation, development, and gene transcription with more than 200 known “reader” domains in the human proteome. We describe our target-class approach to ligand design and discovery for three cancer relevant members of this large family: L3MBTL3 (a Malignant Brain Tumor (MBT) domain containing reader), 53BP1 (a tandem Tudor domain) and CBX7 (a chromo domain). The advantages of a small molecule driven approach to modulating chromatin biology are numerous: temporal resolution; mechanistic flexibility (targeting a specific activity of a protein as opposed to ablating them all with transgenic knock-outs or RNA-interference techniques); ease of delivery; and most significantly, when warranted, a small molecule tool has the potential to provide an immediate transition to a drug discovery effort, potentially cutting years off the time between target validation and therapeutic intervention. UNC1215 binds the MBT domains of L3MBTL3 with a Kd of 120 nM, competitively displacing mono- or dimethyl-lysine containing peptides. This probe is greater than 50-fold selective versus other members of the human MBT family and also demonstrates selectivity against more than 200 other Kme reader domains examined. UNC1215 increases the cellular mobility of GFP-L3MBTL3 fusion proteins and point mutants that disrupt the Kme binding function of GFP-L3MBTL3 phenocopy the effects of UNC1215. The potency, specificity, and cellular effects of UNC1215 establish it as the first cell-active antagonist of a Kme reader domain and a useful chemical probe for biological studies of the function of L3MBTL3 (James, L. I. et al. Nat Chem Biol 2013, 9, 184-191). 53BP1 is a Kme binding protein that plays a central biological role in DNA Damage Repair (DDR) pathway via its recruitment to sites of DNA double strand breaks (DSB). BRCA1 is a checkpoint and DNA damage repair gene that is required for maintenance of genomic integrity, and the inheritance of mutated BRCA1 is a major risk factor for breast and ovarian cancer. The BRCA1 knockout murine model is embryonic lethal and a conditional knockout in mammary glands results in low frequency and long latency of mammary tumor formation. It was recently reported that the BRCA1-null developmental phenotype is rescued when placed on a 53BP1-null background. Adult mice from this model, that are null for both the 53BP1 and BRCA1 genes, age normally and display a very low incidence of tumor formation. Genomic instability can be rescued in 53BP1 knockouts because the homologous recombination (HR) pathway is largely restored in cells lacking both BRCA1 and 53BP1 (Cao, L. et al. Molecular cell 2009, 35 (4), 534-41). Based on this data, small molecule antagonists of 53BP1's biological function could act as viable therapeutics to restore HR in the DDR response in humans with BRAC1 mutations. We will report the first small molecule, fragment-like ligands with selectivity for binding to 53BP1. CBX7 is a chromo domain containing Kme reader that, along with other CBX domains, recruits the PRC1 complex to histone 3, lysine 27 trimethylation sites (H3K27me3) and enables transcriptional silencing downstream of the PRC2 complex which ‘writes’ the H3K27me3 mark via the catalytic activity of EZH2. As EZH2 is a well validated drug target with inhibitors now entering the clinic for the treatment of various cancers, we hypothesize that antagonism of the PRC1 complex recognition of H3K27me3 will phenocopy and perhaps synergize with the activity of EZH2 inhibitors (Konze, K. D. et al. ACS Chemical Biology 2013, 8, 1324-1334). Progress towards a chemical probe to validate CBX7 as a therapeutic target will be presented. The pursuit of high quality chemical probes for KMe reader proteins represents an emerging area that will open new avenues of research in chromatin biology and may in time, translate to new therapeutic approaches. Antagonists of the readers of acetylated lysine (BRD4 bromo domains) derived from pioneering chemical probe efforts (Filippakopoulos, P. et al. Nature 468, 1067-73 (2010)) have recently entered the clinic for the treatment of various malignancies and we hope that our chemical probe work will help to validate Kme readers as novel and significant anti-tumor targets. Citation Format: Lindsey I. James, Jake I. Stuckey, Brandi M. Baughman, Michael T. Perfetti, Samantha G. Pattenden, Brad M. Dickson, Jacqueline L. Norris, Gaofeng Cui, Pavel Mader, Aiping Dong, Yunxiang Mu, Scott B. Rothbart, Brian D. Strahl, Jinrong Min, Peter J. Brown, Dmitri B. Kireev, William P. Janzen, Kevin M. McBride, Mark T. Bedford, Georges Mer, Cheryl H. Arrowsmith, Stephen V. Frye. Targeting chromatin regulation for cancer therapy: progress towards chemical probes for methyl-lysine readers. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr SY08-03. doi:10.1158/1538-7445.AM2015-SY08-03
Abstract PL02-01: Stool DNA detection of colorectal neoplasia: A new high bar for noninvasive screening
Ahlquist, David A.

Cancer Research | August 5, 2015 | Volume: 75 | Issue: 15_Supplement | Pages: PL02-01-PL02-01

10.1158/1538-7445.am2015-pl02-01 Get It

Abstract Stool DNA testing has evolved into a highly accurate and well-validated test for the screen-detection of colorectal neoplasia. An optimized multi-target stool DNA test (MT-sDNA) achieves the same high point-sensitivities as reported with colonoscopy for early-stage colorectal cancer (CRC) and significantly higher sensitivity than by fecal immunochemical blood testing (FIT) for detection of both cancer and advanced precancer. Thus, MT-sDNA sets a new high criterion standard for the noninvasive screen-detection of colorectal neoplasia. With clinical application, MT-sDNA has potential to meaningfully address current gaps in our approach to CRC screening through benefits of its high accuracy on screening effectiveness, user-friendly features on patient compliance, and easy mail-out distribution on test access. After an unprecedented parallel review, the U.S. Food & Drug Administration (FDA) and Center for Medicaid and Medicare Services (CMS) simultaneously endorsed MT-sDNA for general CRC screening in August 2014, and the test is now available for clinical use. This overview briefly summarizes the clinical validation, addresses central clinical questions at implementation, and touches on future applications of stool DNA testing. Despite efforts to date, CRC remains the 2nd leading cause of cancer mortality in the US and screening rates are suboptimal. Conventional screening tools are variably hampered by invasiveness, unpleasant bowel preparation, access limitations, interruption of work routines, and a bias toward left-sided lesion detection which compromise efficacy and participation. There is an imperative to improve screening effectiveness through more accurate, patient-friendly, and accessible approaches. Multi-Target Stool DNA Test (MT-sDNA) Stool DNA testing is grounded in the rational biology of exfoliation, inherent discrimination afforded by tumor-associated genetic and epigenetic alterations, and exquisite analytical sensitivity of new assay methods (Pathology 2012;44:8-0). Key technical innovations leading to the current high test performance include use of a stool buffer to prevent DNA degradation, discriminant new marker panels, and advanced analytical platforms that substantially augment sensitivity. MT-sDNA, an optimized and automated new generation test and the product of an intensive research and development effort, has been described in detail (Clin Gastroenterol Hepatol 2013; 11:1313). It targets two highly discriminant methylated genes (BMP3 and NDRG4), the informative KRAS mutations, a marker for total human DNA (β-actin), and fecal hemoglobin. Quantitative outputs analyzed in a software system yield a positive or negative result based on an established cutoff score. With tightly reproducible results via automation, MT-sDNA avoids the operator variation that hinders quality with endoscopic and subjective in vitro screening methods. This noninvasive test requires no bowel preparation, diet or medication restrictions, or missed work time. Stools can be collected at home and mailed to a central laboratory for processing. Clinical Validation Case-Control Studies. In the first large multicenter study using next generation technology (Gastroenterology 2012;142:248), a prototype MT-sDNA showed high neoplasm detection unaffected by tumor stage or site. In the second study (Clin Gastroenterol Hepatol 2013;11:1313), an optimized MT-sDNA detected 98% of CRC at specificity of 91% and again was unaffected by stage or site. Adenoma detection increased with size and degree of dysplasia: sensitivity for adenomas &gt;1cm was 57%, &gt;2 cm was 73%, and &gt;3 cm was 83%; sensitivity was 83% with high-grade dysplasia (HGD), 94% of which occurred in lesions &gt;2 cm. In a third study (PloS One 2014;9:e85659), MT-sDNA detected 55% of sessile serrated polyps (SSP) &gt;1cm compared to 10% by fecal immune-testing for blood (FIT) at matched specificities. Pivotal Screen-Setting Study. In a multicenter cross-sectional study comprising &gt;10,000 average risk persons from across North America (NEJM 2014;370:1287), MT-sDNA detected 92% of CRC (94% of stage I-II), 69% of HGD, 66% of adenomas &gt;2cm, and 42% of advanced adenomas (&gt;1cm or with villous features) + SSP &gt;1cm. Specificity was 90% based on normal colonoscopy. MT-sDNA superiority over FIT was statistically significant for all lesion categories. Program Performance MT-sDNA could compare favorably with conventional methods in a longitudinal screening program. MT-sDNA achieves high point sensitivity for CRC, similar to that of colonoscopy. However, because it is practical to perform more frequently, MT-sDNA (followed by colonoscopy if positive) could improve program sensitivity by catching aggressive metachronous lesions missed by colonoscopy alone done at typical 10 year intervals. Point sensitivities of MT-sDNA for precancers could translate into very high programmatic sensitivity with repeated screening rounds, as we have estimated (Pathology 2012;44:80), and, therefore, into effective CRC prevention. Finally, MT-sDNA's point specificity of 90%, while lower than the average 95% reported for FIT, bodes well within a screening program as cumulative false-positives are most relevant. For example, MT-sDNA applied every 3 years (frequency supported by early modeling and approved by CMS) would yield roughly 3-4% false-positives/year, fewer than the 5% rate by FIT applied annually. Implementation With the clinical entry of MT-sDNA come both opportunities to improve screening outcomes and a collective responsibility to apply rational principles and evidence-based decision-making to guide and refine its use. Clinical Questions. Multiple questions will be briefly addressed in the oral presentation, including: Can FIT achieve same sensitivity by lowering its specificity?, How does MT-sDNA compare to plasma-based DNA tests?, Is MT-sDNA cost-effective?, What does the clinical use algorithm look like?, and Who would benefit from its use? With respect to the last question, while the FDA approved MT-sDNA for average-risk screening, other indications may evolve. A sound case can be made for interval testing between screening colonoscopies. As currently practiced, screening colonoscopy has a much lower benefit on incidence and mortality reduction from right-sided than left-sided CRC, interval cancers are disproportionately right-sided, and quality metrics of this operator-dependent procedure vary widely. Because of its very high sensitivity for CRC that is unaffected by tumor site and its superior sensitivity over FIT for detection of sessile serrated polyps and those adenomas at greatest risk of progression, MT-sDNA seems well-suited for consideration as an interval test. In instances of inadequately prepared or incomplete colonoscopy, which occur in 15 - 25% of colonoscopies, MT-sDNA testing may offer a convenient follow-up alternative to repeat colonoscopy or other imaging methods, particularly among those reticent or unwilling to undergo repeat bowel preparation and invasive testing. In low CRC risk surveillance populations, such as patients with a single small adenoma, use of MT-sDNA might be explored as a resource-savings approach. Those at high CRC risk represent another potential target group for surveillance. A premise for the recommendation of colonoscopy as the choice for high risk surveillance has been its unparalleled high sensitivity. However, in light of the recent MT-sDNA validation studies showing similarly high point-sensitivity for early-stage CRC and estimates suggesting comparable program-sensitivity for advanced precancers, it is intriguing to re-consider noninvasive surveillance in this setting. Further studies are clearly needed. Meanwhile, in high risk individuals refusing or unable to access colonoscopy and in those with relative contraindications to colonoscopy, surveillance by MT-sDNA might be considered. The Future: Expanded Applications Inflammatory Bowel Disease (IBD). IBD patients are at increased CRC risk, and stool DNA testing may help to improve surveillance detection and compliance rates. In a feasibility study (Aliment Pharmacol Ther 2013;37:546), highly accurate detection of both CRC and HGD in IBD patients was observed by stool assay of methylated DNA markers alone. Supra-colonic Cancers: There remains an enormous unmet need for early detection of cancers above the colon, which collectively exact a death toll 2-times higher than that of CRC in the US and 4-times higher globally. Based on our early observations, stool DNA testing represents a potential strategy to fill this void. If combined with CRC screening, it would be ideal to differentiate upper from lower GI lesions; and preliminary data suggest that site-specific DNA tumor markers can be identified (Gastroenterology 2013;144:S-84). Clearly, more studies are needed and warranted. As stool DNA testing moves from historical promise into primetime, efficient implementation systems and essential linkages with endoscopy will need to be established to achieve highest impact. Logical extensions of this powerful molecular technology open intriguing opportunities to expand its value. Citation Format: David A. Ahlquist. Stool DNA detection of colorectal neoplasia: A new high bar for noninvasive screening. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr PL02-01. doi:10.1158/1538-7445.AM2015-PL02-01
Abstract LB-191: Association of anti-estrogen therapy in breast cancer patients and subsequent risk of rheumatoid arthritis: An electronic health record study
Breitenstein, Matthew K. , Ho, Ming‐Fen , Weinshilboum, Richard M. , Pathak, Jyotishman , Bongartz, Tim, Wang, Liewei , Weinshilboum, Richard M. , Cerhan, James R. , Ingle, James N. , Ho, Ming-Fen

Cancer Research | August 5, 2015 | Volume: 75 | Issue: 15_Supplement | Pages: LB-191-LB-191

10.1158/1538-7445.am2015-lb-191 Get It

Abstract Background: The use of anti-estrogen (AE) therapies (selective estrogen receptor modulators [SERMs], aromatase inhibitors [AIs]) in breast cancer (BC) patients was recently associated with risk of developing rheumatoid arthritis (RA) (J Rheum 2015;42:55-9). We attempted to replicate and extend these results using electronic health record (EHR) enhanced cancer registry data that assessed specific AE therapies and also accounted for potential confounding by age, smoking status, and chemotherapy use. Methods: Using cancer registry and EHR data, we identified a cohort of BC patients who were newly diagnosed and treated at Mayo Clinic Rochester from 1998-2011 and had no previous diagnosis of RA. Smoking status at diagnosis, BC treatments and RA at diagnosis and during follow-up were identified using validated EHR-based algorithms. Hazard ratios (HRs) and 95% confidence intervals (CI) from a multivariate Cox model were used to estimate the association of AE use with risk of RA, controlling for age, smoking status at BC diagnosis, and BC chemotherapy use. Results: The analytic cohort of 9,244 newly diagnosed BC patients treated and followed at Mayo Clinic had a median age at diagnosis of 59 years (range 18-97); 32% were smokers; and 29% were treated with chemotherapy. During a median follow-up of 49 months (range 1-191), 19 patients developed RA. Compared to BC patients not receiving any AE therapy, those receiving AI monotherapy, but not SERM monotherapy or both SERMs and AIs, were at significantly increased risk of developing RA (Table). AE Therapy# of RA Cases / # patientsHR* (95% CI)P-valueNo AE therapy6/4,0711.00 (reference)SERMs only5/2,5371.20 (0.36 - 3.95)0.77AIs only5/7126.37 (1.77 - 22.92)0.005SERMs then AIs3/1,8750.90AI then SERMs0/490.91 (0.21 - 3.86)*Adjusted for age, smoking status and use of chemotherapy Conclusions: Our findings indicate that the use of AIs for BC therapy, but not SERMs or SERMs followed by AIs, is associated with increased risk for development of RA, when controlling for smoking status and use of chemotherapy. While needing replication, these findings suggest a specific role for AIs in RA development and suggest pathways that could be targeted to prevent this potential treatment complication. Citation Format: Matthew K. Breitenstein, Ming-Fen Ho, Richard M. Weinshilboum, James R. Cerhan, Jyotishman Pathak, Tim Bongartz, Liewei Wang, James N. Ingle. Association of anti-estrogen therapy in breast cancer patients and subsequent risk of rheumatoid arthritis: An electronic health record study. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr LB-191. doi:10.1158/1538-7445.AM2015-LB-191
Abstract LB-189: Genetic Epidemiology of Lung Cancer Consortium: genome-wide association study of familial lung cancer cases
Toledo, Diana Marcela , Mandal, Diptasri , Andrade, Mariza de , Kupert, Elena, Gaba, Colette , Anderson, Marshall W., Schwartz, Ann G. , Pinney, Susan M. , Franks, Jennifer M. , Simpson, Claire L. , You, Ming , Bailey‐Wilson, Joan E. , Amos, Christopher I. , de Andrade, Mariza

Cancer Research | August 5, 2015 | Volume: 75 | Issue: 15_Supplement | Pages: LB-189-LB-189

10.1158/1538-7445.am2015-lb-189 Get It

Abstract Several studies have identified common genetic factors that influence susceptibility to lung cancer but no large studies have systematically studied familial lung cancers. The Genetic Epidemiology of Lung Cancer Consortium completed a genome-wide association study (GWAS) using samples from 757 cases and 796 controls, all of European American ancestry, and frequency matched on age and sex. Genotyping was performed by the Center for Inherited Disease Research (CIDR) using an Illumina Human OmniExpressExome-8v1 array. The most significantly associated SNPs were identified in the cases as a whole, and were also stratified by histology (adenocarcinoma and squamous cell carcinoma) and family history (0-1 and 2-5 affected family members). Analysis of all cases and controls identified a large number of SNPs around the CFTR gene that are strongly associated with lung cancer risk. Upon imputation with European Ancestry 1000 genomes data, the most significant SNP in this region is rs43034 (p = 3.89E-07, OR = 0.657) in the promoter region. In addition, an exonic missense SNP, rs213950 (p = 6.32E-07, OR = 0.663), and an intronic SNP with a possible splicing effect, rs213935 (p = 5.20E-07, OR = 0.660) were also identified as possible protective alleles. Analysis by histological subtype identified several rare and exonic SNPs that were specific by histology. We highlight two SNPs, rs114719990 (p = 1.194E-04, OR = 336.8, SETD2, c.3229A&gt;G, p.Thr1077Ala) and rs199710487 (p = 1.124E-04, OR = 366, NTN5, c.656G&gt;A, p.Arg219Gln), that were identified as strongly associated SNPs in cases with histologically confirmed adenocarcinoma, and two SNPs, rs144465058 (p = 1.029E-04, OR = 484.6, ANK3, c.6555G&gt;T, p.Gln2185His) and rs140216112 (p = 1.087E-04, OR = 476, GRIK4, c.1013C&gt;G, p.Ala338Gly), that were identified as top SNPs in cases with histologically confirmed squamous cell carcinoma. The SETD2 gene is thought to be a tumor suppressor gene and variants in this gene have previously been associated with leukemia and glioma (Zhu X et al. 2014, Fontebasso AM et al. 2013), and may now have implications in lung cancer, specifically adenocarcinoma development. In conclusion, we identified SNPs in the CFTR gene that may have a protective effect on lung cancer and several rare and exonic variants that were specific to histology subtype. SNPChrPositionGeneGenomic/ Nucleotide/ Amino acid changeOdds Ratiop-valueCFTR Protective Allelesrs430347117108449CFTRg.117108449T&gt;C; 2.4kb upstream0.6573.89×10−7rs2139507117199533CFTRc.1408G&gt;A; p.Val470Met0.6636.32×10−7rs2139357117178208CFTRc.869+1481A&gt;G0.6605.20×10−7 Citation Format: Diana M. Toledo, Susan M. Pinney, Diptasri Mandal, Mariza de Andrade, Elena Kupert, Jennifer Franks, Colette Gaba, Claire L. Simpson, Ming You, Marshall W. Anderson, Joan E. Bailey-Wilson, Christopher I. Amos, Ann Schwartz. Genetic Epidemiology of Lung Cancer Consortium: genome-wide association study of familial lung cancer cases. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr LB-189. doi:10.1158/1538-7445.AM2015-LB-189
Abstract LB-183: Metformin use does not increase survival of pancreatic cancer patients: A cautionary lesson
Chaiteerakij, Roongruedee , Burch, Patrick, Chaffee, Kari G. , Oberg, Ann L. , Roberts, Lewis R. , Petersen, Gloria M. , Chaiteerakij, Roongruedee , Zhen, David B. , Bamlet, William R. , Roberts, Lewis R

Cancer Research | August 5, 2015 | Volume: 75 | Issue: 15_Supplement | Pages: LB-183-LB-183

10.1158/1538-7445.am2015-lb-183 Get It

Abstract Background: Epidemiologic studies have suggested that metformin use is associated with cancer death reduction. The results for pancreatic ductal adenocarcinoma (PDAC) are inconsistent. Retrospective studies of cancer survival may potentially have unintended biases; due to complexities of diabetes management, metformin use exposure is commonly categorized as simply “yes/no.” Nevertheless, in part based on epidemiologic studies, there are at least 20 open cancer clinical trials that include metformin in a treatment arm. We aimed to study metformin use and survival of patients with PDAC, addressing potential inherent biases. Methods: A retrospective cohort study for the years 2000-2011 was conducted using the patient database of the Mayo Clinic Specialized Programs of Research Excellence (SPORE) in Pancreatic Cancer. 1,360 PDAC patients (59% male; mean age 67) with diabetes were studied; overall survival was the primary outcome. Initiation and duration of metformin use was carefully abstracted from medical records. Patients were categorized into 5 groups based on metformin initiation: (A) Never used, n = 908 (reference group); (B) Metformin started &gt;1 year prior to PDAC diagnosis, n = 84; (C) Metformin started within 1 year prior to PDAC diagnosis, n = 212; (D) Metformin started &lt;30 days post-PDAC diagnosis, n = 104; (E) Metformin started &gt;30 days post PDAC diagnosis, n = 34. Hazard ratios (HR) and 95% confidence intervals (C.I.) for survival differences between groups were computed using Cox proportional hazards models, adjusting for age, sex, disease stage, body mass index, and diagnosis year group. Results: Median survival of patients in Groups B-E was 292 days compared to 308 for Group A; this was not significantly different. However, among 413 resectable patients, metformin users appeared to survive longer than non-users (782 vs. 612 days, p = 0.07). Survival in each group was 308, 245, 249, 243 and 818 days, respectively. Because Group E had already survived &gt;30 days, a bias existed. With Group E excluded, there was no survival difference among the other 4 groups (p = 0.18). Compared to Group A, HR and 95% C.I. for metformin use were 1.08 (0.85-1.37), 0.99 (0.85-1.17), 1.04 (0.83-1.31) and 0.49 (0.33-0.74), for Group B-E, respectively. Conclusions: Our thorough analysis suggests that metformin use does not improve survival of patients with PDAC. The benefit of metformin was observed only in patients who started metformin post-PDAC diagnosis; however, there is an inherent survival bias in this group of patients. Studies of medication exposure and cancer survival warrant very careful and detailed data collection. Researchers should exercise caution when initiating clinical trials based on retrospective epidemiologic studies. Citation Format: Roongruedee Chaiteerakij, David B. Zhen, Patrick A. Burch, Kari G. Chaffee, William R. Bamlet, Ann L. Oberg, Lewis R. Roberts, Gloria M. Petersen. Metformin use does not increase survival of pancreatic cancer patients: A cautionary lesson. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr LB-183. doi:10.1158/1538-7445.AM2015-LB-183
Abstract LB-175: Deep clonal profiling identifies distinct mechanisms of heterogeneity and evolution in breast cancer
Andreozzi, Mariacarla, Francis, Princy, Lenkiewicz, Elizabeth, Champion, Mia D., Laughlin, Brady, Cunliffe, Heather E. , McCullough, Ann E. , Barrett, Michael T. , Pockaj, Barbara A. , Anderson, Karen S.

Cancer Research | August 5, 2015 | Volume: 75 | Issue: 15_Supplement | Pages: LB-175-LB-175

10.1158/1538-7445.am2015-lb-175 Get It

Abstract Background: Breast tumors exhibit intratumor heterogeneity resulting in targeted therapy resistance and other challenges in disease management. To address the sources of heterogeneity, we performed a unique, in-depth analysis of clonal architecture in primary chemoradiation-naïve breast cancers. We combined DNA content-based flow cytometry and ploidy analysis with aCGH and whole exome next-generation sequencing (NGS) in multiple biopsies from the tumors and involved lymph nodes (LNs). Material and methods: We sorted nuclei from distinct populations of diploid, tetraploid, and aneuploid cells in surgical tumor samples from three chemoradiation-naïve patients. Each sorted tumor cell population was interrogated with aCGH and whole exome NGS. In Patient #1, we sorted and interrogated the genomes of tumor populations from 12 fresh frozen sections morphologically mapped from within a HER2+, ER+, PR- primary invasive ductal carcinoma (IDC) of histological grade 3 with LN involvement and 2-3 sections from 2 out of 5 LNs. In Patient #2, 11 morphologically mapped fresh frozen sections were analyzed from a grade 2, ER+, PR+, HER2+, BRCA2 mutant LN- IDC. In parallel, matching samples were processed for IHC assays. In Patient #3 biopsies from a grade 2 ER+, PR+ primary tumor were profiled. Results: The 18 primary and LN biopsies from Patient #1 fell into 6 distinct ploidy groups albeit with aberrant but homogenous aCGH profiles, characterized by SARC amplification and homozygous deletions in ROBO1 and ROBO2. In contrast a dominant ploidy was identified throughout 10 biopsies in Patient #2 but with heterogeneous aCGH profiles. Patient #3 had a clonal homozygous deletion in Numb in each of 4 tumor biopsies. Mutation profiles obtained through exome sequencing further confirmed that ploidy was the main driver in Patient #1 whereas copy number aberrations played the key role in Patient #2 with the BRCA2 mutation (R3129X). A dendrogram based on exome variant calls of the aneuploid populations in Patient #1 strongly correlated with ploidy group and further revealed the specific clonal population characterized by a 5N ploidy and homozygous mutations in TP53 and PIK3CA as the progenitor to the ploidies present in the distant LNs. Strikingly, patients #1 and #2 were HER2 wild type across their clonal populations, contradicting IHC staining in a single core biopsy. Conclusions:Rather than inferring the presence of distinct tumor cell populations, our flow-sorting based approach of first identifying clonal populations and then interrogating their genomes, provides an objective method of exploring the sources and clinical significance of tumor heterogeneity. Our approach of clonal analysis has broad implications in the study of tumor heterogeneity and the identification of drivers in breast and other solid tumors that can advance more effective treatment and clinical management of patients with this disease. Citation Format: MARIACARLA ANDREOZZI, Princy Francis, Elizabeth Lenkiewicz, Mia Champion, Brady Laughlin, Karen Anderson, Heather Cunliffe, Ann E. McCullough, Michael T. Barrett, Barbara Pockaj. Deep clonal profiling identifies distinct mechanisms of heterogeneity and evolution in breast cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr LB-175. doi:10.1158/1538-7445.AM2015-LB-175